Trademark Details For RELESIUM (Serial Number 98722747)

  •  Home
  •  Print
RELESIUM
1
10
5
0
Serial Number  United States - USPTO 98722747
Registration Number 8404059
Mark
RELESIUM
Filing Date Aug-28-2024
Status
Registered  
REGISTERED (700)
REGISTERED
Attorney Name
TTAB
0




005Pharmaceuticals

U.S Class(es): 005, 006, 018, 044, 046, 051, 052

Class Status: Active

First Use: Feb-18-2025

First Use in Commerce: Feb-18-2025





Correspondences

NameMichael A. Geller DLA Piper LLP (US)
AddressP.O. Box 64807 Chicago, IL 60606-0089 United States

Prosecution History

DateDescription
Action Tags    
Action tags indicate key events in the prosecution history. View details of the related office action file by clicking on the icons.
Code
Aug-28-2024NEW APPLICATION ENTERED   NWAPI
Aug-28-2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED   NWOSI
Mar-04-2025ASSIGNED TO EXAMINER   DOCKD
Mar-05-2025APPROVED FOR PUB - PRINCIPAL REGISTER   CNSAP
Mar-26-2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED   NONPE
Apr-01-2025PUBLISHED FOR OPPOSITION   PUBOA
Apr-01-2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED   NPUBE
May-27-2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT   NOAME
Nov-12-2025TEAS STATEMENT OF USE RECEIVED   EISUI
Apr-15-2026CASE ASSIGNED TO INTENT TO USE PARALEGAL   AITUA
Nov-12-2025USE AMENDMENT FILED   IUAFS
Apr-17-2026STATEMENT OF USE PROCESSING COMPLETE   SUPCI
Apr-28-2026SU - NON-FINAL ACTION - WRITTEN   CNRTW
Apr-28-2026NON-FINAL ACTION E-MAILED   GNRTO
Apr-28-2026NOTIFICATION OF NON-FINAL ACTION E-MAILED   GNRNO
Jul-27-2026APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED   XELRI
Jul-27-2026APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED   XELGO
Jul-30-2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED   CNPRP
Jul-30-2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED   SUNAE
Aug-18-2026REGISTERED-PRINCIPAL REGISTER   R.PRA
Aug-18-2026NOTICE OF REGISTRATION CONFIRMATION EMAILED   NRCCE